{"id":24881,"date":"2026-04-21T09:38:42","date_gmt":"2026-04-21T07:38:42","guid":{"rendered":"https:\/\/adragos-pharma.com\/?p=24881"},"modified":"2026-04-21T11:30:42","modified_gmt":"2026-04-21T09:30:42","slug":"cdmo-pre-filled-syringe-manufacturing-europe","status":"publish","type":"post","link":"https:\/\/adragos-pharma.com\/cdmo-pre-filled-syringe-manufacturing-europe\/","title":{"rendered":"Pre-Filled Syringe Manufacturing at Commercial Scale"},"content":{"rendered":"<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n     TABLE OF CONTENTS\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n\n<nav style=\"background-color: #f0f0fa; border-left: 4px solid #1C1C75; padding: 20px 24px; margin-bottom: 36px; border-radius: 4px;\" aria-label=\"Page contents\">\n<p style=\"font-weight: bold; margin: 0 0 12px 0; color: #1c1c75; font-size: 1rem;\">Contents<\/p>\n\n<ol style=\"margin: 0; padding-left: 20px; line-height: 2;\">\n \t<li><a style=\"color: #1c1c75; text-decoration: none;\" href=\"#aseptic-fill-finish\">Aseptic Fill-Finish for Commercial Pre-Filled Syringe Programmes<\/a><\/li>\n \t<li><a style=\"color: #1c1c75; text-decoration: none;\" href=\"#supporting-formats\">Supporting Sterile Injectable Formats<\/a><\/li>\n \t<li><a style=\"color: #1c1c75; text-decoration: none;\" href=\"#manufacturing-site\">Manufacturing Site: Maisons-Alfort, France<\/a><\/li>\n \t<li><a style=\"color: #1c1c75; text-decoration: none;\" href=\"#regulatory-compliance\">Regulatory Certification and Global Compliance<\/a><\/li>\n \t<li><a style=\"color: #1c1c75; text-decoration: none;\" href=\"#supply-reliability\">Supply Reliability for Global Programmes<\/a><\/li>\n \t<li><a style=\"color: #1c1c75; text-decoration: none;\" href=\"#evaluating-cdmo\">Evaluating a European CDMO for Pre-Filled Syringes<\/a><\/li>\n \t<li><a style=\"color: #1c1c75; text-decoration: none;\" href=\"#contact\">Discuss Your Programme with Adragos Pharma<\/a><\/li>\n<\/ol>\n<\/nav><!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n     H1\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<h1>Pre-Filled Syringe Manufacturing at Commercial Scale<\/h1>\n<!-- VERIFY: confirm homepage URL structure -->\n<a title=\"Adragos Pharma \u2013 Contract Development and Manufacturing Organisation\" href=\"https:\/\/www.adragos-pharma.com\/\">Adragos Pharma <\/a>provides commercial-scale aseptic fill-finish services for pre-filled syringes at our <a title=\"Maisons-Alfort Sterile Manufacturing Site | Adragos Pharma\" href=\"https:\/\/www.adragos-pharma.com\/maisons-alfort\/\">Maisons-Alfort facility in France<\/a>. Operating under <a title=\"EU Good Manufacturing Practice | European Medicines Agency\" href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/compliance\/good-manufacturing-practice\" target=\"_blank\" rel=\"noopener noreferrer\">EU Good Manufacturing Practice<\/a>, certified by the <a title=\"ANSM \u2013 Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9\" href=\"https:\/\/ansm.sante.fr\/en\/\" target=\"_blank\" rel=\"noopener noreferrer\">Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 <\/a>and positioned as a Food and Drug Administration-ready site, our facility supports global pharmaceutical programmes that require reliable, compliant sterile drug product manufacturing in Europe.\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n     SECTION 1: ASEPTIC FILL-FINISH\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<h2 id=\"aseptic-fill-finish\">Aseptic Fill-Finish for Commercial Pre-Filled Syringe Programmes<\/h2>\nPre-filled syringes are the primary sterile dosage form manufactured at our Maisons-Alfort site. Our aseptic fill-finish operations are designed to meet the throughput, quality and regulatory demands of commercial-scale supply programmes, integrating advanced contamination control technologies with robust process systems.\n<h3 id=\"rabs\">Active Restricted Access Barrier System Technology<\/h3>\nOur facility is equipped with active Restricted Access Barrier System technology. Active Restricted Access Barrier Systems provide a physical and aerodynamic barrier between the operator and the critical filling zone, maintaining International Organization for Standardization Grade A conditions throughout the fill-finish process.\n<h3 id=\"cip-sip\">Clean-in-Place and Sterilise-in-Place Systems<\/h3>\nAll critical process equipment at Maisons-Alfort is supported by Clean-in-Place and Sterilise-in-Place systems. These integrated cleaning and sterilisation cycles minimise manual intervention, reduce contamination risk and support process reproducibility across commercial batches, contributing to consistent product quality at scale.\n<h3 id=\"high-speed-filling\">High-Speed Aseptic Filling<\/h3>\nOur line is configured for high-speed aseptic filling, providing the throughput capacity required to support commercial supply programmes and the flexibility to accommodate varying demand profiles across global markets.\n<h3 id=\"visual-inspection\">Advanced Visual Inspection<\/h3>\nFollowing aseptic filling, each unit undergoes advanced visual inspection to detect particulate matter, container integrity defects and fill anomalies. Our inspection capability is aligned with the standards set out under\n<a title=\"EU GMP Annex 1 \u2013 Manufacture of Sterile Medicinal Products | EMA\" href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/compliance\/good-manufacturing-practice\" target=\"_blank\" rel=\"noopener noreferrer\">EU Good Manufacturing Practice Annex 1 <\/a>and supports the quality assurance requirements of regulatory submissions across multiple markets.\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n     SECTION 2: SUPPORTING STERILE FORMATS\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<h2 id=\"supporting-formats\">Supporting Sterile Injectable Formats<\/h2>\nWhilst pre-filled syringes represent the primary fill-finish capability at Maisons-Alfort, the facility also manufactures liquid vials and lyophilised vials. Our large-scale freeze-drying capability serves programmes where lyophilisation is required to achieve the necessary product stability profile. This range of sterile format capability allows clients to consolidate manufacturing across multiple product types within a single European site.\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n     SECTION 3: MANUFACTURING SITE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<h2 id=\"manufacturing-site\">Manufacturing Site: Maisons-Alfort, France<\/h2>\nOur <a title=\"Maisons-Alfort Sterile Manufacturing Facility | Adragos Pharma\" href=\"https:\/\/www.adragos-pharma.com\/maisons-alfort\/\">Maisons-Alfort facility <\/a>is a purpose-built sterile manufacturing site located in the greater Paris region of France. The site integrates:\n<ul>\n \t<li>High-speed aseptic filling for pre-filled syringes<\/li>\n \t<li>Large-scale freeze-drying for lyophilised vials<\/li>\n \t<li>Advanced visual inspection<\/li>\n \t<li>Dedicated packaging halls<\/li>\n \t<li>Robust logistics infrastructure to support global commercial distribution<\/li>\n<\/ul>\nThe facility is structured to deliver continuity of supply, combining manufacturing capacity with the quality systems and logistics capability required for reliable international commercial programmes.\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n     SECTION 4: REGULATORY COMPLIANCE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<h2 id=\"regulatory-compliance\">Regulatory Certification and Global Compliance<\/h2>\n<h3 id=\"eu-gmp\">EU Good Manufacturing Practice and ANSM Certification<\/h3>\nOur Maisons-Alfort site operates under <a title=\"EU Good Manufacturing Practice Guidelines | European Medicines Agency\" href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/compliance\/good-manufacturing-practice\" target=\"_blank\" rel=\"noopener noreferrer\">EU Good Manufacturing Practice <\/a>and holds certification from the\n<a title=\"ANSM \u2013 French National Medicines Regulatory Authority\" href=\"https:\/\/ansm.sante.fr\/en\/\" target=\"_blank\" rel=\"noopener noreferrer\">Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9<\/a>, the French national medicines regulatory authority. This certification confirms site compliance with EU Good Manufacturing Practice requirements and supports product registration and supply across the European Economic Area. The site maintains active audit readiness as a standard operational requirement.\n<h3 id=\"fda-ready\">Food and Drug Administration-Ready Site<\/h3>\nIn addition to EU Good Manufacturing Practice compliance, our facility is positioned as a\n<a title=\"Current Good Manufacturing Practice Regulations | US Food and Drug Administration\" href=\"https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/current-good-manufacturing-practice-cgmp-regulations\" target=\"_blank\" rel=\"noopener noreferrer\">Food and Drug Administration<\/a>-ready manufacturing site. This status enables clients to pursue United States market registration and commercial supply without requiring a change of manufacturing site prior to regulatory submission.\n<h3 id=\"international\">International Regulatory Recognition<\/h3>\nOur Maisons-Alfort facility is recognised by regulatory authorities across multiple markets, providing clients with a single European manufacturing base from which to serve global distribution programmes. Current regulatory approvals and certifications include:\n<h4>Asia<\/h4>\n<ul>\n \t<li><a title=\"National Medical Products Administration | People&#039;s Republic of China\" href=\"https:\/\/www.nmpa.gov.cn\/\" target=\"_blank\" rel=\"noopener noreferrer\">NMPA<\/a>\n(People&#8217;s Republic of China)<\/li>\n \t<li><a title=\"Ministry of Food and Drug Safety | Republic of Korea\" href=\"https:\/\/www.mfds.go.kr\/eng\/index.do\" target=\"_blank\" rel=\"noopener noreferrer\">MFDS<\/a>\n(Republic of Korea)<\/li>\n \t<li><a title=\"Saudi Food and Drug Authority | Kingdom of Saudi Arabia\" href=\"https:\/\/www.sfda.gov.sa\/en\/\" target=\"_blank\" rel=\"noopener noreferrer\">SFDA<\/a>\n(Kingdom of Saudi Arabia)<\/li>\n \t<li>NCE (Republic of Kazakhstan)<\/li>\n \t<li><a title=\"TITCK \u2013 Pharmaceutical and Medical Device Agency | Republic of Turkey\" href=\"https:\/\/www.titck.gov.tr\/\" target=\"_blank\" rel=\"noopener noreferrer\">TITCK<\/a>\n(Republic of Turkey)<\/li>\n<\/ul>\n<h4>Africa<\/h4>\n<ul>\n \t<li><a title=\"National Agency for Food and Drug Administration and Control | Federal Republic of Nigeria\" href=\"https:\/\/www.nafdac.gov.ng\/\" target=\"_blank\" rel=\"noopener noreferrer\">NAFDAC<\/a>\n(Federal Republic of Nigeria)<\/li>\n \t<li><a title=\"National Drug Authority | Republic of Uganda\" href=\"https:\/\/www.nda.or.ug\/\" target=\"_blank\" rel=\"noopener noreferrer\">NDA-UG<\/a>\n(Republic of Uganda)<\/li>\n \t<li><a title=\"Pharmacy and Poisons Board | Republic of Kenya\" href=\"https:\/\/www.pharmacyboardkenya.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">PPB<\/a>\n(Republic of Kenya)<\/li>\n<\/ul>\n<h4>Other Markets<\/h4>\n<ul>\n \t<li><a title=\"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria | Federative Republic of Brazil\" href=\"https:\/\/www.gov.br\/anvisa\/pt-br\" target=\"_blank\" rel=\"noopener noreferrer\">ANVISA<\/a>\n(Federative Republic of Brazil)<\/li>\n \t<li>MHRF (Russian Federation)<\/li>\n \t<li>Republic of Belarus<\/li>\n<\/ul>\nThis breadth of regulatory recognition reduces the complexity of multi-market supply strategies and enables clients to expand into established and emerging markets from a single, compliant European facility.\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n     SECTION 5: SUPPLY RELIABILITY\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<h2 id=\"supply-reliability\">Supply Reliability for Global Programmes<\/h2>\nFor any commercial sterile injectable programme, the ability to maintain uninterrupted supply is as commercially critical as technical manufacturing capability. Our Maisons-Alfort facility is designed to support reliable, on-time delivery at commercial scale, underpinned by robust logistics and quality systems that maintain product integrity from the point of manufacture through to global distribution.\n\nDedicated packaging halls at the site support the final stages of commercial supply preparation, ensuring product is ready for distribution in line with the requirements of each target market.\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n     SECTION 6: EVALUATING A CDMO\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<h2 id=\"evaluating-cdmo\">Evaluating a European Contract Development and Manufacturing Organisation for Pre-Filled Syringes<\/h2>\nPharmaceutical and biotechnology organisations selecting a European contract development and manufacturing organisation for commercial sterile injectables require a combination of technical capability, regulatory credibility and supply assurance. The key criteria that <a title=\"Adragos Pharma \u2013 European CDMO\" href=\"https:\/\/www.adragos-pharma.com\/\">Adragos Pharma <\/a>addresses at Maisons-Alfort include:\n<ul>\n \t<li>Commercial-scale aseptic fill-finish for pre-filled syringes, supported by active Restricted Access Barrier System and Clean-in-Place \/ Sterilise-in-Place systems<\/li>\n \t<li><a title=\"EU Good Manufacturing Practice | EMA\" href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/compliance\/good-manufacturing-practice\" target=\"_blank\" rel=\"noopener noreferrer\">EU Good Manufacturing Practice<\/a>\ncertification by the Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 with maintained audit readiness<\/li>\n \t<li>Food and Drug Administration-ready site status for programmes targeting the United States market<\/li>\n \t<li>Multi-authority regulatory recognition spanning Asia, Africa and additional international markets<\/li>\n \t<li>Integrated sterile manufacturing capability including liquid and lyophilised vials for consolidated site strategies<\/li>\n \t<li>Dedicated packaging halls and logistics infrastructure to support global commercial supply<\/li>\n<\/ul>\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n     SECTION 7: CALL TO ACTION\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<h2 id=\"contact\">Discuss Your Pre-Filled Syringe Programme with Adragos Pharma<\/h2>\nIf you are evaluating European contract development and manufacturing organisation partners for a commercial pre-filled syringe programme, our team at Maisons-Alfort is available to discuss your requirements in detail.\n\n<section class=\"wp-block-adragos-blocks-footer-cta max-w-screen-lg bg-light mx-8 md:mx-auto px-8 py-12 text-center mt-3 mb-12 md:mb-16 rounded-xl\"><h2 class=\"\">Download the Maisons-Alfort brochure<\/h2><p class=\"subtitle font-light m-auto max-w-screen-sm py-6\"> And learn more about the site\u2019s PFS manufacturing capabilities, sterile vial\u00a0expertise\u00a0and integrated service platform<\/p><div class=\"flex flex-col md:flex-row justify-center gap-4\"><a href=\"https:\/\/share-eu1.hsforms.com\/1hym2_RZ9S16Cod3hkA-NfAfxkpu\" class=\"cta-link inline-block adragos-button text-white has-primary-background-color text-center\" target=\"_blank\" rel=\"noopener\">Click here<\/a><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"<p>Contents Aseptic Fill-Finish for Commercial Pre-Filled Syringe Programmes Supporting Sterile Injectable Formats Manufacturing Site: Maisons-Alfort, France Regulatory Certification and Global Compliance Supply Reliability for Global Programmes Evaluating a European CDMO for Pre-Filled Syringes Discuss Your Programme with Adragos Pharma Pre-Filled [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":24382,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[13],"tags":[376],"topics":[356],"locations":[370],"experts":[],"class_list":["post-24881","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","tag-pre-filled-syringes","topics-prefilled-syringes","locations-maisons-alfort"],"_links":{"self":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/24881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/comments?post=24881"}],"version-history":[{"count":2,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/24881\/revisions"}],"predecessor-version":[{"id":24883,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/24881\/revisions\/24883"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media\/24382"}],"wp:attachment":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media?parent=24881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/categories?post=24881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/tags?post=24881"},{"taxonomy":"topics","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/topics?post=24881"},{"taxonomy":"locations","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/locations?post=24881"},{"taxonomy":"experts","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/experts?post=24881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}